GeoVax Labs Inc. (GOVX)
NASDAQ: GOVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GOVX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.84M
- EPS (TTM)
- -$8.84
- Dividend yield
- None
- 52-week range
- 0.2705 – 15.75
- Day range
- 0.2705 – 0.2929
- Volume / Avg
- 230.74K / 771.47K
- Beta
- —
- Shares outstanding
- 10.10M
52-week range
GOVX stock today
Shares of GeoVax Labs (GOVX) finished lower on Oct 9 at $0.281, a drop of 1.95% or $0.0056 per share, versus the S&P 500's 0.59% gain. Trading was light, with 230.74K shares changing hands, about 30% of the average daily volume. At this level, GOVX sits near the bottom of its 52-week range of $0.2705 to $15.75: 98.2% below the high and 3.9% above the low.
GeoVax Labs has posted a net loss over the last twelve months (EPS of -$8.84), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About GeoVax Labs
Company profileGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. David Alan Dodd
- Headquarters
- Smyrna, GA
- Employees
- 19
- Website
- geovax.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$10.00+3458.72%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
GeoVax Labs peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SILOSilo Pharma Inc. | 1.47 | +1.38% | $3.02M | vs GOVX |
| REVBRevelation Biosciences Inc. | 0.7599 | -2.58% | $3.03M | vs GOVX |
| MBIOMustang Bio Inc. | 0.4001 | -2.44% | $3.03M | vs GOVX |
| MTNBMatinas Biopharma Holdings Inc. | 2.87 | +1.41% | $2.81M | vs GOVX |
| PRFXPRF Technologies Ltd. | 0.8789 | +2.35% | $3.08M | vs GOVX |
| KAPAKairos Pharma Ltd. | 0.8103 | -15.55% | $2.74M | vs GOVX |
| APVOAptevo Therapeutics Inc. | 1.79 | -0.56% | $3.24M | vs GOVX |
| CVKDCadrenal Therapeutics Inc. | 0.9101 | -2.10% | $3.25M | vs GOVX |
Indexes, lists and sector
GeoVax Labs stock FAQ
What is GeoVax Labs's stock price today?
GOVX last traded at $0.281 as of Oct 9, 4:00 PM EDT, down 1.95% on the day. Prices are delayed at least 15 minutes.
Who is GeoVax Labs's CEO?
Mr. David Alan Dodd is the chief executive officer of GeoVax Labs Inc., which has about 19 employees.
What is the GOVX 52-week high?
The 52-week high for GOVX is $15.75 and the 52-week low is $0.2705. The stock is currently 98.2% below its high.